Astrazeneca Ab

Anna Kristoffersson

Stephen Connolly

Martin Hemmerling

Nafizal Hossain

Grigorios Nikitidis

Lena Elisabeth Ripa

Igor Shamovsky

Susanne Elisabeth Berglund

Johan Rune Michael Lundkvist

Andiappan Murugan

Peter Olof Sjö

Martin Lindsjö

Lena Kristina Bergstrom

Mark David Ashton

Jon Meigh

Johan Rune Lundkvist

The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).

Chemical compounds

The present invention provides a compound of a formula (I): 

The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD). 

The invention provides compounds of formula wherein R, R, R, R, R, R, L, X and Y are as defined in the specification; together with processes and intermediates for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

2-pyridone compounds

Growing community of inventors

Macclesfield, United Kingdom

Anna Kristoffersson